This led us to think that the NLRP3 inflammasome and its regulatory pathways may be an ideal target for treatment of chronic degenerative diseases like NASH with multiple pathological processes. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.